<div id="readability-page-1"><p>Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) have received an average recommendation of &#34;Moderate Buy&#34; from the eight ratings firms that are presently  covering the stock, Marketbeat reports. Two research analysts have rated the stock with a sell rating, five have given a buy rating and one  has given a strong buy rating to  the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $50.00.</p><ul><li>Zai Lab Stock Has Fallen to Value Levels </li></ul><p>A number of research analysts recently issued reports on the company. Cantor Fitzgerald dropped their price target on Zai Lab from $55.00 to $37.00 and set an &#34;overweight&#34; rating on the stock in a research note on Friday, February 27th. Weiss Ratings  reiterated a &#34;sell (d-)&#34; rating on shares of Zai Lab in a research note on Wednesday, January 21st. UBS Group began coverage on Zai Lab in a report on Wednesday, January 7th. They issued a &#34;buy&#34; rating and a $35.00 price objective for the company. JPMorgan Chase &amp; Co. lowered their target price on shares of Zai Lab from $39.00 to $32.00 and set an &#34;overweight&#34; rating on the stock in a research report on Wednesday, March 18th. Finally, Jefferies Financial Group upgraded shares of Zai Lab to a &#34;strong-buy&#34; rating in a research report on Monday, January 19th.</p><p><b>Read Our Latest Analysis on Zai Lab</b></p><h2>Zai Lab Price Performance</h2><p>Shares of ZLAB opened at $18.81 on Wednesday. Zai Lab has a 1-year low of $15.96 and a 1-year high of $44.34. The stock has a market cap of $2.12 billion, a PE ratio of -11.68 and a beta of 0.85. The firm has a fifty day moving average price of $18.56 and a 200 day moving average price of $21.93. </p><p>Zai Lab (NASDAQ:ZLAB - Get Free Report) last issued its quarterly earnings data on Saturday, February 14th. The company reported ($0.50) earnings per share (EPS) for the quarter. Zai Lab had a negative return on equity of 22.81% and a negative net margin of 38.15%.The firm had revenue of $127.60 million for the quarter.  As a group, equities analysts expect that  Zai Lab will post -2.58 EPS for the current fiscal year. </p><h2>Insider Buying and Selling at Zai Lab</h2><p>In other news, insider Rafael Amado sold 2,957 shares of the stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $18.63, for a total transaction of $55,088.91. Following the completion of the sale, the insider owned 44,757 shares in the company, valued at approximately $833,822.91. This represents a 6.20% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this link. Also, insider Joshua L. Smiley sold 1,966 shares of the firm's stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $18.63, for a total value of $36,626.58. Following the transaction, the insider directly owned 91,026 shares in the company, valued at approximately $1,695,814.38. This represents a 2.11% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 6,626 shares of company stock valued at $123,442. Company insiders own  4.96% of the company's stock. </p><h2>Institutional Trading of Zai Lab</h2><p>An institutional investor recently bought a new position in Zai Lab stock. SG Americas Securities LLC bought a new stake in  Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 9,754 shares of the company's stock, valued at approximately $331,000. 41.65% of the stock is owned by hedge funds and other institutional investors. </p><h2>Zai Lab Company Profile</h2> (Get Free Report)<p>Zai Lab Ltd <span>NASDAQ: ZLAB<span></span></span> is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&amp;D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company's end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.  </p><p>The company's marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton's tyrosine kinase inhibitor approved for several B-cell malignancies.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Zai Lab</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WkxBQg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WkxBQg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Zai Lab Right Now?</h2><p>Before you consider Zai Lab, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zai Lab wasn't on the list.</p><p>While Zai Lab currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ARKG

SBIO

<p>Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) has received an average recommendation of "Moderate Buy" from eight brokerages. Analysts have mixed ratings, with two sell, five buy, and one strong buy. The average price target is $50.00. Recent reports show price targets have been adjusted, with Cantor Fitzgerald lowering theirs from $55.00 to $37.00. ZLAB shares opened at $18.81, with a 1-year low of $15.96 and a high of $44.34. The company reported a quarterly EPS of ($0.50) and had revenue of $127.60 million. Insiders have sold shares recently, and institutional ownership stands at 41.65%.</p>

- Zai Lab Limited (NASDAQ:ZLAB) has received a "Moderate Buy" average recommendation from eight ratings firms, with two sell ratings and five buy ratings.  
- The stock has fallen significantly, with a recent average price target of $50, and analysts citing declines in price targets, including a cut from $55 to $37 by Cantor Fitzgerald.  
- Zai Lab reported a revenue of $127.60 million and a loss of $0.50 EPS for the latest quarter, leading to an expectation of -2.58 EPS for the current fiscal year.

Market Beat

VanEck Biotech ETF

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

Invesco Nasdaq Biotechnology ETF

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

Zai Lab

iShares Biotechnology ETF

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Average Recommendation of "Moderate Buy" by Brokerages